BioAge Labs Inc. (Ticker: BIOA) is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, Azelaprag, is an orally available small molecule currently being tested in clinical trials for its potential to improve weight loss and muscle function. Azelaprag is also being developed to treat obesity in combination with GLP-1 agonists, such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy.

BioAge Labs will list on September 26, 2024, on the NASDAQ Global Market. The company is now offering 10.5 million shares, up from the previously planned 7.5 million shares, at a price range of $17.00 to $19.00, aiming to raise up to $199.5 million. The expected market capitalization at the offer is approximately $639.7 million. Affiliates of existing investor Sofinnova Venture Partners are expected to invest up to $1.4 million in the public offering and purchase shares worth around $10.6 million in a concurrent private placement at the IPO price. The offering is managed by Goldman Sachs, Morgan Stanley, Jefferies, and Citigroup.